Pharmaceuticals

Durect’s Lalcostosterol Receives FDA Breakthrough Treatment Designation for Severe Alcohol-Related Hepatitis

bexib
By bexib 0 Min Read

Going forward, Durect plans to incorporate feedback from the FDA into the design of its Phase 3 trial.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Would you like to start a food truck business? What you need to know about costs (2024)
Next Article Current Markets, Land Prices, and the Importance of Trade Access, March 16, 2024 – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

China commission recommends termination of Beijing’s PNTR status
Manufacturing
Financial institution budgets for next-generation MFA solutions in 2025
Banking
42% of financial institutions plan to invest in customer identity solutions in 2025
Banking
Apple Pay, other tech companies come under CFPB regulatory oversight
Banking